Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020, with a specific reporting date of July 10, 2020. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2020-07-09 | Ordinary Shares (25p each) | £16.1010 | 160 shares (aggregate) | London Stock Exchange (XLON) |
Note: The aggregate volume of 160 shares represents the sum of 11 individual transactions. Most executives acquired 16 shares (8 partnership + 8 matching), while three individuals acquired 14 shares (7 partnership + 7 matching).
Material Changes
The filing does not provide comparative data against prior periods. It reports initial notifications of share acquisitions executed on a single date (July 9, 2020) for eleven specific executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions are routine acquisitions under the Company's Share Reward Plan.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions are acquisitions of Ordinary Shares under the Share Reward Plan, not open market sales or discretionary purchases.
- Participants: Transactions involved 11 individuals, including CEO Emma Walmsley, President of Global Vaccines Richard Connor, and CEO of ViiV Healthcare Daria Waterhouse.
- Valuation: All shares were acquired at a uniform price of £16.1010 per share.
- Scope: This filing is a regulatory disclosure of insider holdings changes and does not reflect the company's overall financial performance for the period.